Mesoglycan, Vascular Reactivity and Metabolic Syndrome
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to characterize the action of mesoglycan on vascular endothelium
through the non-invasive assessment of vascular reactivity humeral artery by comparing
effects of mesoglycan on Flow Mediated Dilatation (FMD) of the humeral artery between a group
of patients with metabolic syndrome assuming placebo and a group of patient with metabolic
syndrome assuming mesoglycan; firstly after administration of the drug/placebo
intramuscularly, and then, in a study of medium-term after oral intake of drug/placebo. The
selection of patients with metabolic syndrome is related to the fact that this syndrome is
associated with alterations in endothelial function and a high incidence of cardiovascular
events. So it is a condition that offers the opportunity to explore the hypothesis that the
mesoglycan may have a favorable effect on early vascular alterations that precede clinical
events.